<![CDATA[Duvelisib/Azacitidine Combo Shows Encouraging Activity in T-Cell Lymphoma]]>

Phase 1positiveDuvelisibAzacitidinePositive

AI Analysis

Summary

A phase 1 dose-escalation trial demonstrated that duvelisib combined with azacitidine produced a 46% overall response rate in patients with relapsed/refractory T-cell lymphoma, showing encouraging activity for the combination approach.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

46% overall response rate in relapsed/refractory T-cell lymphoma

Importance:5/10

Sentiment:

0.65

Phase 1T-cell lymphomacombination therapydose-escalation trialoncology

Read the original article

Published by Cancer Network on August 11, 2026 4:00 PM

Read Original